| 词条 | Labetuzumab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 458270329 | image = | type = mab | mab_type = mab | source = zu/o | target = carcinoembryonic antigen | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 219649-07-7 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D08936 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | chemical_formula = | molecular_weight = }}Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2] Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis. This drug was developed by Immunomedics, Inc. References1. ^Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association. {{Monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^http://www.cancer.gov/drugdictionary?cdrid=692828 1 : Monoclonal antibodies for tumors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。